<DOC>
	<DOCNO>NCT01167010</DOCNO>
	<brief_summary>The primary objective compare Eurofarma Alenia formulation regard impact pulmonary function mild moderate persistent asthma patient secondary objective compare three study formulation regard clinical control symptoms patient ' compliance treatment .</brief_summary>
	<brief_title>A Non-inferiority , Comparative Study Between Foraseq® , Eurofarma´s Formoterol/Budesonide Alenia® Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Sign ICF ; ≥ 12 year old ; Have diagnosis mild moderate persistent asthma diagnosis , per GINA classification ( www.ginasthma.com ) ,18 symptom least 6 month clinically stable least 1 month ACQ7 test &lt; 3,0 ; Current use inhale corticosteroid ( equivalent 1000 µg beclomethasone dipropionate ) whether associate longterm β2 adrenergic relief medication ( salbutamol equivalent ) ; Initial FEV1 least 50 % normal value expect ; Serum cortisol evaluation within normal limit Use oral parenteral corticosteroid within last 3 month study ; Hospitalization need due asthma within last 3 month study ; Active smoker , define consumption cigarette , pipe , cigar , form smoking amount within last 3 month ; Presence serious comorbidities , cardiovascular , renal , liver , neurological , neoplastic , hematological , infectious , dermatologic , neurological , psychiatric disease , chronic respiratory disease asthma ; Recent participation ( &lt; 6 month ) expect participation clinical trial involve drug product nature study consist form intervention treatment asthma ; Intolerance allergy component drug evaluate study ; Pregnant lactate woman ; Chronic use routine βblockers orally intravenously , include ophthalmic solution .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>